Impact of the insulin and glucose content of the postoperative fluid on the outcome after pediatric cardiac surgery by Lex, Dániel et al.
 Interventional Medicine & Applied Science, Vol. 6 (4), pp. 160–169 (2014) 
 DOI: 10.1556/IMAS.6.2014.4.4   ISSN 2061-1617 © 2014 Akadémiai Kiadó, Budapest 160
O R I G I N A L  PA P E R
Impact of the insulin and glucose content
of the postoperative ﬂ uid on the outcome 
after pediatric cardiac surgery
DÁNIEL J. LEX1,*, PÉTER SZÁNTÓ2, TAMÁS BREUER2, ROLAND TÓTH2, MIHÁLY GERGELY2, 
ZSOLT PRODÁN2, ERZSÉBET SÁPI2, ANDRÁS SZATMÁRI2, TAMÁS SZÁNTÓ3, JÁNOS GÁL4, 
ANDREA SZÉKELY4
1School of PhD Studies, Semmelweis University, Budapest, Hungary
2Gottsegen György Hungarian Institute of Cardiology, Budapest, Hungary
3Faculty of Information Technology, Pázmány Péter Catholic University, Budapest, Hungary
4Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary
*Corresponding author:  Dániel J. Lex; Semmelweis University, Budapest, Hungary; E-mail: lexdani@gmail.com
(Received: January 21, 2014; Revised manuscript received: September 3, 2014; Accepted: September 3, 2014)
Abstract: Introduction: The aim of this study was to investigate the role of the insulin and glucose content of the maintenance ﬂ uid in inﬂ uencing 
the outcomes of pediatric patients undergoing heart surgery. Methods: A total of 2063 consecutive pediatric patients undergoing cardiac surgery 
were screened between 2003 and 2008. A dextrose and an insulin propensity-matched group were constructed. In the dextrose model, 5% and 
10% dextrose maintenance infusions were compared below 20 kg of weight. Results: A total of 171 and 298 pairs of patients were matched in 
the insulin and glucose model, respectively. Mortality was lower in the insulin group (12.9% vs. 7%, p = 0.049). The insulin group had longer 
intensive care unit (ICU) stay [days, 10.9 (5.8–18.4) vs. 13.7 (8.2–21), p = 0.003], hospital stay [days, 19.8 (13.6–26.6) vs. 22.7 (17.6–29.7), 
p < 0.01], duration of mechanical ventilation [hours, 67 (19–140) vs. 107 (45–176), p = 0.006], and the incidence of severe infections (18.1% vs. 
28.7%, p = 0.01) and dialysis (11.7% vs. 24%, p = 0.001) was higher. In the dextrose model, the incidence of pulmonary complications (13.09% vs. 
22.5%, p < 0.01), low cardiac output (17.11% vs. 30.9%, p < 0.01), and severe infections (10.07% vs. 20.5%, p < 0.01) was higher, and the duration 
of the hospital stay [days, 16.4 (13.1–21.6) vs. 18.1 (13.8–24.6), p < 0.01] was longer in the 10% dextrose group. Conclusions: Insulin treatment 
appeared to decrease mortality, and lower glucose content was associated with lower occurrence of adverse events.
Keywords: cardiac surgery, pediatrics, insulin, glucose, dextrose, maintenance infusion, critical care, heart surgery, children
Introduction
Hyperglycemia and poor glycemic control are major risk 
factors for increased morbidity and mortality in various 
clinical settings, including pediatric patients undergoing 
cardiac surgery. Recent studies have identiﬁ ed associa-
tions between critical illness and hyperglycemia (CIH) 
and adverse outcomes after congenital heart surgery 
[1–3]. Although tight glycemic control has been shown 
to improve outcomes in some studies, these results have 
triggered controversy because of the high incidence of 
hypoglycemic events in the pediatric population [4, 5]. 
Approaches with less stringent glycemic targets have 
been introduced for pediatric intensive care unit pa-
tients with low risks of hypoglycemia, but the beneﬁ t of 
this more liberal glycemic control is still questionable. 
Therefore, the aim of this study was to investigate the 
eff ect of liberal management of CIH with insulin use 
and to evaluate an alternative or complementary path 
to insulin use (i.e., the reduction of the amount of glu-
cose infusion) in a large retrospective cohort of pediat-
ric patients following cardiac surgery. To assess whether 
the insulin usage or the glucose infusion reduction im-
proved outcomes, we compared in-hospital mortalities 
and postoperative morbidities in propensity-matched 
pediatric cardiac surgery patients.
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Methods
Patients and samples
Between January 2003 and December 2008, 2063 con-
secutive pediatric patients (<18-year old) who underwent 
cardiac surgery and were admitted to our cardiac inten-
sive care unit were screened after Institutional Review 
Board approval. The board waived the need for parental 
informed consent. All the perioperative data were ob-
tained by a prospectively collected institutional database, 
which collected data for quality control measurements. 
After deleting the cases with missing data, 1667 (insulin 
model) and 1401 (dextrose model) patients remained for 
further analysis. None of the patients who were included 
in the present analyses had a history of diabetes mellitus. 
The categorical and continuous predictor variables that 
were included in the model are shown in Table I.
The cardiac surgical procedures were graded by ap-
plying the Risk Adjustment for Congenital Heart Sur-
gery (RACHS-1) method. To quantify the amount of 
cardiac support, we calculated the modiﬁ ed inotropic 
score, as described by Wernovsky [6]: dopamine + do-
butamine + (epinephrine*100) + (norepinephrine*100) 
+ (milrinone*20), using peak infusion rates measured in 
micrograms/kilogram/min. Dextrose-containing infu-
sions (10% dextrose for patients <20 kg and 5% dextrose 
for patients >20 kg) had been administered postopera-
tively before the policy change was implemented (5% for 
each patient). Insulin infusions of 0.1 IU/kg/h were 
initiated if the BG (blood glucose) values of the patients 
exceeded 10 mmol/L at two consecutive measurements. 
Blood glucose measurements were performed via point-
of-care equipment from whole blood samples on the day 
of surgery (D0), on the ﬁ rst postoperative day (D1), and 
on the second postoperative day (D2), for an average of 
six to eight times daily.
Death was deﬁ ned as the demise from any cause. The 
combined endpoint of the study was deﬁ ned as death 
after arrival at the intensive care unit (ICU) (including 
patients who died after having been transferred to an-
other hospital) or after development of multiple organ 
dysfunction, which consisted of any two of the following 
complications: 1) postoperative low output syndrome 
(clinical signs: tachycardia, oliguria, cold extremities or 
cardiac arrest, and an increase in the base deﬁ cit of >4 on 
two consecutive blood gas measurements); 2) pulmo-
nary complication (deﬁ ned as non-infectious); 3) non-
vascular oxygenation problems (atelectasia, pneumotho-
rax, chylothorax, and phrenic paresis); 4) renal failure 
(peritoneal dialysis, or hemodialysis); 5) infections (cath-
eter-related and deep-sternal wound infections, positive 
blood cultures, or sepsis); and 6) neurological events 
(convulsions without a prior history or hemorrhage or 
infarcts demonstrated by cranial imaging), which were 
also included in the composite outcome [7].
Statistical analysis
The data were summarized using descriptive statistics, 
which were expressed as counts and percentages for 
the categorical variables and as means and standard de-
viations (SD) for the continuous data. Patients with 
missing data regarding their baseline covariates and 
clinical outcomes were excluded from the analysis. 
Demographic and perioperative diff erences between 
the patients were compared using the chi-square and 
t-tests where appropriate. Because the patients were 
not randomly allocated to the treatment or control 
groups, they were not comparable with respect to the 
important covariates. To overcome the bias resulting 
from the design of this study, we constructed two pro-
pensity score models (one for receiving insulin and one 
for receiving a 10% or 5% dextrose infusion) to adjust 
for diff erences in the characteristics between the treat-
ed patients and the non-treated patients. The propen-
sity scores were developed using a non-parsimonious 
multivariable logistic regression model, with treatment 
considered as the outcome and all the risk factors that 
potentially confounded the treatment eff ect consid-
ered as the predictor variables. The treated patients 
were matched to the non-treated patients with simi-
lar propensity scores. A 1:1 nearest-neighbor greedy 
matching without replacement was employed (Stata/
PSMATCH2) to form pairs, using calipers with a width 
equal to 0.25 of the standard deviation of the logit of 
the propensity score. The 171 and 298 matched pairs 
were analyzed for diff erences in their baseline charac-
teristics and in the aforementioned predeﬁ ned out-
come variables. The outcomes and measured covari-
ates were compared between the groups via a paired 
t-test for the continuous variables and McNemar’s test 
for the categorical data. To assess whether the propen-
sity score model had been correctly speciﬁ ed and the 
balance of the baseline characteristics between the two 
groups had been achieved, the standardized diff erences 
were estimated. Across the 16 baseline covariates, the 
standardized diff erences ranged from a low of −0.07 to 
a high of 0.09 in the insulin model and from a low of 
−0.07 to a high of 0.06 in the dextrose-delivery model, 
indicating that the means and prevalence of the vari-
ables were very similar between the groups in the dif-
ferent models. The selection of the predictor variables 
was based on our previous results [8], and a custom 
Java code generator determined all the possible varia-
tions of the confounders that yielded a standardized 
diff erence within the range of 10%. All of the tests 
were two-sided. We considered p < 0.05 to be signiﬁ -
cant. The analyses were conducted using Stata SE 12 
(Stata, College Station, TX), the SPSS 16.0 statistical 
software (SPSS, Inc., Chicago, IL), and STATISTICA 
(data analysis software system) (StatSoft, Inc. [2007], 
version 8.0, www.statsoft.com).
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Results
The model of insulin treatment
During the 5-year period, 2060 patients underwent op-
erations. The analyzed database (1667 patients) in the in-
sulin model contained the data of 298 (17.8%) neonates, 
577 (34.6%) infants, and 792 (47.5%) children. In the 
study population of 1667 patients, 198 (11.8%) patients 
were treated with insulin. Sixty patients (3.5%) died. 
Renal replacement therapy was required in 97 (5.8%) 
patients. The demographic and perioperative character-
istics of the patients, clustered by the insulin treatment, 
are listed in Table I. Compared with the patients who 
were not subjected to continuous insulin control, the pa-
tients who received insulin underwent a more complex 
surgery with a long duration of the cardiopulmonary 
bypass procedure, were more likely to exhibit cyanosis, 
and required mechanical ventilation before surgery. The 
insulin patients received larger amounts of inotropic 
drugs and more transfusions, and they required nitric 
oxide and prostaglandins more frequently. The patients 
in the insulin group were younger, and one-ﬁ fth of them 
underwent acute surgeries and rethoracotomies. The 
measured blood glucose levels on the day of surgery and 
on the ﬁ rst and second postoperative days in the insu-
lin group were higher than in the control patients (da-
ta not shown). The propensity score derivation model 
comprised 16 variables, including the following: gender 
(male), logarithmic transformation of age, acute surgery, 
resternotomy, delayed sternal closure, cyanosis, RACHS 
score, preoperative pulmonary hypertension, preopera-
tive ICU stay (days), cardiopulmonary bypass time (min-
utes), preoperative prostaglandin administration, maxi-
mum blood glucose value (mmol/L) on the day of sur-
gery, post-bypass inotropic score, requirement for nitric 
oxide, transfusion (mL/kg), and use of aprotinin. These 
variables were discriminatively quantiﬁ ed by measur-
ing the receiver-operating-characteristic area (c-index, 
0.87). Through this model, 171 (of 198) insulin patients 
were matched to 171 (of 1469) non-insulin (control) 
patients. Table II presents the outcomes of the patients 
before and after propensity matching. Before propensity 
matching, the patients who were treated with insulin ex-
hibited a higher mortality and morbidity compared with 
the non-insulin-treated patients. After propensity-score 
matching, the standardized diff erences for all the mea-
sured variables were less than 10%, suggesting complete 
comparability of the preoperative and perioperative char-
acteristics across the groups (Fig. 1). The occurrence of 
infection (18.1% vs. 28.7%, p = 0.0143) and the require-
ment for dialysis (11.7% vs. 24%, p < 0.01) were higher 
in the insulin group. The duration of the mechanical 
ventilation (hours) and the length of the ICU (days) and 
hospital stay (days) were also greater compared with the 
non-insulin patients. The in-hospital mortality (12.9% T
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Fig. 1. Standardized diff erences in the values of the predictor variables – insulin model
Fig. 2. Standardized diff erences in the values of the predictor variables – dextrose model
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vs. 7%, p = 0.049) was lower in the insulin-treated group. 
No diff erence was observed in the time of death after 
surgery between the control and insulin-treated groups 
[median days: 2 (IQR: 1–7.75) vs. 6.5 (2.5–13.5); p = 
0.12, respectively].
The model of dextrose delivery
We compared the patients who weighed less than 20 kg 
and who received 10% dextrose solutions (77.2%) to 
those who received 5% dextrose infusions (22.7%). The 
dextrose model contained the data of 308 (21.9%) neo-
nates, 583 (41.6%) infants, and 510 (36.4%) children. In 
this population of 1401 patients, 319 (22.7%) patients 
were treated with a 5% dextrose solution (D5). Fifty-
six patients (3.9%) died. Renal replacement therapy was 
required in 92 (6.5%) patients. The demographic and 
perioperative characteristics of the patients are listed in 
Table III. The D5 patients received higher amounts of 
inotropic drugs, were more likely to exhibit cyanosis, 
and required prostaglandins more frequently. The maxi-
mum BG levels (mmol/L) on the day of surgery (7.7 vs. 
8.7, p < 0.01), on the ﬁ rst postoperative day (6.7 vs. 8.2, 
p < 0.01), and on the second postoperative day (6 vs. 
7.4, p < 0.01) were also higher in the group in which 
the daily ﬂ uid intake was maintained by 10% dextrose 
infusions. The propensity score model for dextrose deliv-
ery included the following 16 variables: gender (male), 
body mass (kg), logarithmic transformation of age, acute 
surgery, resternotomy, delayed sternal closure, cyanosis, 
RACHS score, preoperative pulmonary hypertension, 
preoperative ICU stay (days), cardiopulmonary bypass 
time (minutes), preoperative prostaglandin administra-
tion, post-bypass inotropic score, requirement for nitric 
oxide, transfusion (mL/kg), and use of aprotinin. The 
model was discriminative (c-index, 0.734). Using this 
model, 298 (of 319) D5 patients were matched to 298 
(of 1082) D10 patients. Table IV lists the outcomes of 
the patients before and after propensity matching. The 
standardized diff erences for all the measured variables 
were also less than 10% in this model, suggesting com-
plete comparability of the preoperative and perioperative 
characteristics across the groups, as in the insulin model 
(Fig. 2).
Discussion
Using propensity score methods, we successfully 
matched a relatively large number of patients who were 
treated with continuous insulin therapy after pediatric 
cardiac surgery to a group of patients (comparable with 
respect to every measured covariate) who were not in 
the insulin model. We also successfully matched patients 
with a ﬂ uid balance maintained by D10 dextrose solu-
tions to patients treated with D5-containing ﬂ uids. After 
matching, we found that insulin treatment was associ-
ated with a lower mortality rate but was linked to an 
increased duration of mechanical ventilation, as well as 
the hospital and ICU stay, and an increased rate of renal 
failure and severe infection. We also found that patients 
who received a reduced carbohydrate calorie intake had 
a decreased LOS and exhibited lower rates of infection, 
pulmonary complications, low-output syndrome, and 
composite outcomes.
Until the early years of the twenty-ﬁ rst century, hyper-
glycemia was not routinely controlled in the ICU, except 
among patients with known diabetes mellitus. After sev-
eral studies demonstrated that the management of gly-
cemic disturbances in patients with DM is a useful prac-
tice [9–13], investigators attempted to prove the same 
beneﬁ t of insulin treatment in non-diabetic, critically ill 
patients. Subsequently, the concept that hyperglycemia 
in non-DM subjects as an adaptive response to stress is 
a beneﬁ cial condition became outdated, and the previ-
ous passive approach to hyperglycemia was no longer 
optimal for any ICU patients, regardless of whether they 
had DM [14]. Hyperglycemia occurs frequently, and it 
is associated with increased morbidity and mortality in 
critically ill adults and pediatric patients [14–19]. Insulin 
therapy has become a favored practice in ICUs. How-
ever, certain studies of the adult population have dem-
onstrated that tight glycemic control is inferior to liberal 
control [20], thus raising awareness of the high risk of 
hypoglycemia. By contrast, a randomized controlled trial 
in children, conducted by Vlasselaers et al., has revealed 
associated reductions in mortality and the length of stay 
(LOS), and tight glycemic control has been determined 
to cause a severe increase in the risk of hypoglycemia in 
pediatric intensive care unit (PICU) children [5]. Ac-
cording to the latest randomized trial with continuous 
glucose monitoring, intensive insulin therapy targeting 
a glucose level of 4.4 to 6.1 mmol/L does not reduce 
the mortality, infection rates, or LOS compared with 
standard care in pediatric patients after cardiac surgery 
[21]. These results contrast with the ﬁ ndings of Vlasse-
laers et al. because the glycemic target range is diff erent 
– although this fact might not fully explain the discrep-
ancies between the studies. Apparently, there are various 
conclusions regarding these results, and it is not surpris-
ing that considerable disparity exists among the attitudes 
toward stress hyperglycemia and its management in the 
critically ill pediatric population.
The retrospective analysis in the present study re-
vealed that continuous insulin therapy in this large co-
hort of pediatric cardiac surgery patients was associated 
with increased rates of infection, renal failure, longer 
durations of mechanical ventilation and LOS, and fewer 
occurrences of in-hospital death. Some studies suggest 
that the beneﬁ cial eff ects of insulin therapy are due more 
to blood glucose control than to the insulin itself [22]. 
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An increased amount of insulin was positively associated 
with death in the ICU, regardless of the prevailing BG 
level – which again supports the previous hypothesis 
that blood glucose control is the dominant factor in im-
proving mortality [23]. It is possible that higher insulin 
requirements are strong markers of the disease severity, 
reﬂ ected as a higher morbidity and mortality. However, 
our results contradict these observations by demonstrat-
ing a survival beneﬁ t in the insulin group despite the 
fact that these patients exhibited higher BG levels than 
the control group. Nevertheless, it is diffi  cult, particu-
larly in an observational cohort, to clearly distinguish the 
contribution of glucose control and the direct eff ect of 
insulin on the decrease in mortality and morbidity. In 
this case, we believe that the insulin therapy acted as a 
surrogate for other covariates that were associated with 
the outcome.
Therefore, the increased rates of infection and renal 
failure in the insulin group even after propensity score 
matching (although the diff erence in all the outcomes 
narrowed after matching) suggest that we could not rule 
out all bias and that the patients treated with insulin 
were in worse metabolic condition and were even more 
severely ill. However, insulin therapy exhibits conﬁ rmed 
anti-apoptotic, anti-inﬂ ammatory, endothelium-protec-
tive, anti-thrombotic, and anti-ﬁ brinolytic properties, as 
well as many other reportedly beneﬁ cial and direct ef-
fects [24–28] that (without knowing the exact mecha-
nism) could have contributed to the improved mortality 
outcomes in our cohort. These ﬁ ndings contradict the 
only randomized trial [21] in this particular pediatric 
population, in which tight glycemic control was com-
pared to standard care with the aid of continuous glu-
cose monitoring that concentrated on preventing hypo-
glycemia after cardiac surgery.
The other fact to be considered is that, in addition to 
peripheral and hepatic insulin resistance, stress-induced 
catecholamine release, commonly used ICU drugs (such 
as steroids and vasopressors) [29–31], and excessive 
glucose-containing infusions for ﬂ uid maintenance also 
compound the problem and play an important role in 
precipitating high blood glucose concentrations [32–
37]. Dextrose delivery is considered necessary to pre-
vent hypoglycemia, glycogen breakdown, and the ampli-
ﬁ cation of protein catabolism in the critically ill, fasting 
child, but not in as high concentrations as has been used 
in the past. Many studies have reported that a reduced 
glucose intake can prevent hypoglycemic episodes while 
maintaining the blood glucose concentration within the 
normal range [38–41]. Our results conﬁ rm these ﬁ nd-
ings. Furthermore, a recent investigation by Verbruggen 
et al. [42] revealed that lowering the dextrose load in 
patients may be an alternative or complementary meth-
od to insulin therapy for glycemic control. Selecting the 
glucose concentration is a forced choice between avoid-
ing hypoglycemia and avoiding hyperglycemia. Indeed, T
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many investigators have found that the delivery of high 
concentrations of dextrose leads to elevated blood glu-
cose levels, which are associated with higher morbidity 
rates during the perioperative period [35, 41, 43]. We 
believe that the beneﬁ cial eff ects are attributable to the 
signiﬁ cantly lower blood glucose levels, albeit still hyper-
glycemic, in the D5 group. In this setting, the number 
of patients who were treated with insulin was relatively 
low (11.7%, not shown), and 67% of them were in the 
D10 group. Sixty-ﬁ ve percent of the patients were un-
der 1 year of age. In a recent clinical trial, even 0.9% 
dextrose was proven to provide a glucose load suffi  cient 
for preventing hypoglycemia in infants in intraoperative 
settings [44]. However, this concentration, as a part of 
ﬂ uid maintenance, might not be adequate for certain 
clinical situations in which the metabolic rate severely 
increases. In addition to considering the risk of hypogly-
cemia due to the low carbohydrate reserves and higher 
metabolic rates in these patients, avoiding an excessive 
rate of dextrose administration is beneﬁ cial.
Study limitations
This study had several limitations. Because we conduct-
ed an observational study, residual confounding is possi-
ble. However, we succeeded in balancing the diff erences 
between the treatment and control groups based on the 
standardized diff erences. The propensity score matching 
controlled only for the observed covariates, and there 
might have been unmeasured confounders that we did 
not consider. Indeed, bias related to improvements in 
managing congenital heart diseases, preheld beliefs re-
garding controlling stress hyperglycemia throughout the 
study period, or unmeasured clinical severity might have 
also played an important role in undermining our con-
clusions. The other limitation is that the calorie-intake 
policy changed during the study period, and this diff er-
ence was not incorporated into the insulin propensity 
model; moreover, the choice regarding insulin use was 
often driven by the preference of the attending physician 
rather than by the protocol. In this single center study, 
we observed patients who had markedly heterogeneous 
congenital heart diseases and baseline characteristics, 
and we successfully matched 86% of the patients who 
received insulin therapy. Thus, our results may be inter-
preted as generalizable, which is one of the strengths of 
our study – in addition to its large cohort of pediatric 
cardiac patients, the prospectively collected database, 
and the well-deﬁ ned postoperative complications.
Summary
Using the propensity score method, we found that the 
liberal glycemic control of critical-illness hyperglycemia 
via continuous insulin administration in the pediatric 
cardiac-surgical population does not reduce the occur-
rence of postoperative complications that are believed to 
be associated with elevated BG levels; however, a sur-
vival beneﬁ t was observed. Furthermore, the reduction 
of the carbohydrate caloric intake might be a reasonable 
supplement to liberal and non-intensive insulin therapy, 
considering the aforementioned controversies and the 
latest randomized trial [21] that has addressed the man-
agement of critical-illness hyperglycemia in children after 
cardiac surgery.
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